CAV-PVP chemotherapy and sequential thoracic irradiation (TI) for patients with limited (LD) small cell lung cancer (SCLC)

H. Ueoka; T. Ohnoshi; S. Hiraki; H. Kamei; M. Tabata; T. Shibayama; K. Miyatake; K. Gemba; J. Hiyama; J. Kimura

CAV-PVP chemotherapy and sequential thoracic irradiation (TI) for patients with limited (LD) small cell lung cancer (SCLC)

H. Ueoka, T. Ohnoshi, S. Hiraki, H. Kamei, M. Tabata, T. Shibayama, K. Miyatake, K. Gemba, J. Hiyama, J. Kimura

University Hospital

Research output: Contribution to journal › Article › peer-review

Abstract

In order to assess the effectiveness of sequential TI for the treatment of LD SCLC, we analyzed 69 patients who had received CAV-PVP chemotherapy consisting of cyclophosphamide, adriamycin, vincristine, cisplatin and etoposide, plus sequential TI between 1986 and 1992. TI was delivered at a total dose of 50 Gy, 5 fractions/week for 5 weeks, once patients achieved a maximal response to chemotherapy. Responding patients also received PCI at a total dose of 30 Gy, 5 fractions/week for 3 weeks. Thirty patients achieved CR by chemotherapy and an additional 10 achieved CR after TI, resulting in a CR rate of 58.0%. Of 40 patients achieving CR, 24 have relapsed so far; the primary (in 15) and the brain (in 4) were the major sites of relapse despite TI and PCI. The median survival time was 18.4 months, with a 2-year survival rate of 39% and 3-year survival rate of 20%. Almost all the patients encountered grade 3 or grade 4 leukopenia while receiving chemotherapy, but the toxicity of TI was generaly mild. This treatment is useful for patients with LD SCLC.

Original language	English
Pages (from-to)	218-224
Number of pages	7
Journal	Japanese Journal of Thoracic Diseases
Volume	31
Issue number	SUPPL.
Publication status	Published - Dec 1 1993

Keywords

chemo-radiotherapy
sequential therapy
small cell lung cancer

ASJC Scopus subject areas

Pulmonary and Respiratory Medicine

UN SDGs

This output contributes to the following Sustainable Development Goal(s)

Fingerprint Dive into the research topics of 'CAV-PVP chemotherapy and sequential thoracic irradiation (TI) for patients with limited (LD) small cell lung cancer (SCLC)'. Together they form a unique fingerprint.

Cite this

CAV-PVP chemotherapy and sequential thoracic irradiation (TI) for patients with limited (LD) small cell lung cancer (SCLC). / Ueoka, H.; Ohnoshi, T.; Hiraki, S.; Kamei, H.; Tabata, M.; Shibayama, T.; Miyatake, K.; Gemba, K.; Hiyama, J.; Kimura, J.

In: Japanese Journal of Thoracic Diseases, Vol. 31, No. SUPPL., 01.12.1993, p. 218-224.

Research output: Contribution to journal › Article › peer-review

@article{4fd8b7c387754df3a1c5548111a64b16,

title = "CAV-PVP chemotherapy and sequential thoracic irradiation (TI) for patients with limited (LD) small cell lung cancer (SCLC)",

abstract = "In order to assess the effectiveness of sequential TI for the treatment of LD SCLC, we analyzed 69 patients who had received CAV-PVP chemotherapy consisting of cyclophosphamide, adriamycin, vincristine, cisplatin and etoposide, plus sequential TI between 1986 and 1992. TI was delivered at a total dose of 50 Gy, 5 fractions/week for 5 weeks, once patients achieved a maximal response to chemotherapy. Responding patients also received PCI at a total dose of 30 Gy, 5 fractions/week for 3 weeks. Thirty patients achieved CR by chemotherapy and an additional 10 achieved CR after TI, resulting in a CR rate of 58.0%. Of 40 patients achieving CR, 24 have relapsed so far; the primary (in 15) and the brain (in 4) were the major sites of relapse despite TI and PCI. The median survival time was 18.4 months, with a 2-year survival rate of 39% and 3-year survival rate of 20%. Almost all the patients encountered grade 3 or grade 4 leukopenia while receiving chemotherapy, but the toxicity of TI was generaly mild. This treatment is useful for patients with LD SCLC.",

keywords = "chemo-radiotherapy, sequential therapy, small cell lung cancer",

author = "H. Ueoka and T. Ohnoshi and S. Hiraki and H. Kamei and M. Tabata and T. Shibayama and K. Miyatake and K. Gemba and J. Hiyama and J. Kimura",

year = "1993",

month = dec,

day = "1",

language = "English",

volume = "31",

pages = "218--224",

journal = "Respiratory Investigation",

issn = "2212-5345",

publisher = "Elsevier BV",

number = "SUPPL.",

}

TY - JOUR

T1 - CAV-PVP chemotherapy and sequential thoracic irradiation (TI) for patients with limited (LD) small cell lung cancer (SCLC)

AU - Ueoka, H.

AU - Ohnoshi, T.

AU - Hiraki, S.

AU - Kamei, H.

AU - Tabata, M.

AU - Shibayama, T.

AU - Miyatake, K.

AU - Gemba, K.

AU - Hiyama, J.

AU - Kimura, J.

PY - 1993/12/1

Y1 - 1993/12/1

N2 - In order to assess the effectiveness of sequential TI for the treatment of LD SCLC, we analyzed 69 patients who had received CAV-PVP chemotherapy consisting of cyclophosphamide, adriamycin, vincristine, cisplatin and etoposide, plus sequential TI between 1986 and 1992. TI was delivered at a total dose of 50 Gy, 5 fractions/week for 5 weeks, once patients achieved a maximal response to chemotherapy. Responding patients also received PCI at a total dose of 30 Gy, 5 fractions/week for 3 weeks. Thirty patients achieved CR by chemotherapy and an additional 10 achieved CR after TI, resulting in a CR rate of 58.0%. Of 40 patients achieving CR, 24 have relapsed so far; the primary (in 15) and the brain (in 4) were the major sites of relapse despite TI and PCI. The median survival time was 18.4 months, with a 2-year survival rate of 39% and 3-year survival rate of 20%. Almost all the patients encountered grade 3 or grade 4 leukopenia while receiving chemotherapy, but the toxicity of TI was generaly mild. This treatment is useful for patients with LD SCLC.

AB - In order to assess the effectiveness of sequential TI for the treatment of LD SCLC, we analyzed 69 patients who had received CAV-PVP chemotherapy consisting of cyclophosphamide, adriamycin, vincristine, cisplatin and etoposide, plus sequential TI between 1986 and 1992. TI was delivered at a total dose of 50 Gy, 5 fractions/week for 5 weeks, once patients achieved a maximal response to chemotherapy. Responding patients also received PCI at a total dose of 30 Gy, 5 fractions/week for 3 weeks. Thirty patients achieved CR by chemotherapy and an additional 10 achieved CR after TI, resulting in a CR rate of 58.0%. Of 40 patients achieving CR, 24 have relapsed so far; the primary (in 15) and the brain (in 4) were the major sites of relapse despite TI and PCI. The median survival time was 18.4 months, with a 2-year survival rate of 39% and 3-year survival rate of 20%. Almost all the patients encountered grade 3 or grade 4 leukopenia while receiving chemotherapy, but the toxicity of TI was generaly mild. This treatment is useful for patients with LD SCLC.

KW - chemo-radiotherapy

KW - sequential therapy

KW - small cell lung cancer

UR - http://www.scopus.com/inward/record.url?scp=0027849721&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027849721&partnerID=8YFLogxK

M3 - Article

C2 - 8007469

AN - SCOPUS:0027849721

VL - 31

SP - 218

EP - 224

JO - Respiratory Investigation

JF - Respiratory Investigation

SN - 2212-5345

IS - SUPPL.

ER -

CAV-PVP chemotherapy and sequential thoracic irradiation (TI) for patients with limited (LD) small cell lung cancer (SCLC)

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Other files and links

Cite this